Related Experiment Videos
Pharmacokinetics of oligonucleotides
Ciba Foundation Symposium
|January 1, 1997
Summary
Antisense oligonucleotides (ASOs) effectiveness relies on their pharmacokinetics and stability. Modified ASOs show improved in vivo stability and potential for oral administration, enhancing therapeutic applications.
Area of Science:
- Pharmacology
- Drug Development
- Molecular Biology
Background:
- The therapeutic efficacy of antisense oligonucleotides (ASOs) is intrinsically linked to their pharmacokinetic properties, including absorption, distribution, metabolism, excretion, and safety.
- Understanding these parameters is crucial for optimizing dosing regimens and predicting potential toxicities during chronic administration.
Purpose of the Study:
- To investigate the pharmacokinetic profiles and in vivo stability of various antisense oligonucleotide modifications.
- To compare the characteristics of standard phosphorothioate oligonucleotides with end-modified and centrally modified mixed-backbone oligonucleotides (MBOs).
Main Methods:
- Administration of phosphorothioate oligonucleotides and modified MBOs via intravenous, subcutaneous, intradermal, and intraperitoneal routes in animal models (mice, rats, monkeys).
- Analysis of plasma and tissue concentrations, degradation patterns, and elimination routes (primarily urinary).
- Evaluation of stability and oral bioavailability of modified ASOs.
Main Results:
- Phosphorothioate oligonucleotides exhibit time- and tissue-dependent degradation from both ends, rapid distribution, and retention in most tissues, with urine as the primary elimination route.
- Standard ASOs have a short plasma half-life in humans.
- End-modified MBOs demonstrate enhanced in vivo stability and potential for oral administration compared to parent ASOs, while retaining similar pharmacokinetic profiles.
- Centrally modified MBOs exhibit controlled degradation and elimination in rats.
Conclusions:
- The pharmacokinetics of ASOs are influenced by their sequence, linkage chemistry, and secondary structure.
- Modification strategies, such as end-modification in MBOs, significantly improve ASO stability and offer potential for alternative administration routes, including oral delivery.
- Further research into ASO pharmacokinetics is essential for advancing their therapeutic potential.